Management of breast cancer in the genome era

Annual Review of Medicine

Volumn 60, Issue , 2009, Pages 153-165

  Morrow, Phuong Khanh H ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Epigenetics; Genetic polymorphism; Micrometastases; Prognostic profiling

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENDOXIFEN; EPIRUBICIN; FLUOROURACIL; FLUOXYMESTERONE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER GROWTH; CANCER RISK; CLINICAL TRIAL; DIARRHEA; DISTANT METASTASIS; DRUG BLOOD LEVEL; EPIGENETICS; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOME ANALYSIS; HAND FOOT SYNDROME; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STOMATITIS; TREATMENT RESPONSE; TUMOR CELL;

BREAST NEOPLASMS; FEMALE; GENOMICS; HUMANS; PROGNOSIS;

EID: 67650741782     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.60.061107.145152     Document Type: Review

References (56)

1. Jemal A, Siegel R,Ward E, et al. 2008. Cancer statistics, 2008. CA Cancer J. Clin. 58:71-96
2. Berry DA, Cronin KA, Plevritis SK, et al. 2005. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med. 353:1784-92
3. Perou CM, Sorlie T, Eisen MB, et al. 2000. Molecular portraits of human breast tumours. Nature 406:747-52
4. Sorlie T, Perou CM, Tibshirani R, et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98:10869-74
5. Sorlie T,Tibshirani R, Parker J, et al. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100:8418-23
6. Carey LA, Dees EC, Sawyer L, et al. 2007. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13:2329-34
7. van 't Veer LJ, Dai H, van de Vijver MJ, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-36
8. van de Vijver MJ, He YD, van 't Veer LJ, et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009
9. Buyse M, Loi S, van 't Veer L, et al. 2006. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 98:1183-92
10. Paik S, Shak S, Tang G, et al. 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351:2817-26
11. Hassett MJ, O'Malley AJ, Pakes JR, et al. 2006. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J. Natl. Cancer Inst. 98:1108-17
12. Wang Y, Klijn JG, Zhang Y, et al. 2005. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-79
13. Foekens JA, Atkins D, Zhang Y, et al. 2006. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24:1665-71
14. Desmedt C, Piette F, Loi S, et al. 2007. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13:3207-14
15. Dai H, van 't Veer L, Lamb J, et al. 2005. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 65:4059-66
16. Chang HY, Sneddon JB, Alizadeh AA, et al. 2004. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2:E7
17. Chang HY, Nuyten DS, Sneddon JB, et al. 2005. Robustness, scalability, and integration of a woundresponse gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 102:3738-43
18. Fan C, Oh DS,Wessels L, et al. 2006. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355:560-69
19. Gianni L, Zambetti M, Clark K, et al. 2005. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 23:7265-77
20. Paik S, Tang G, Shak S, et al. 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24:3726-34
21. Hess KR, Anderson K, Symmans WF, et al. 2006. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24:4236-44
22. Chang JC,Wooten EC, Tsimelzon A, et al. 2003. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-69
23. Chang JC, Wooten EC, Tsimelzon A, et al. 2005. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J. Clin. Oncol. 23:1169-77
24. Iwao-Koizumi K, Matoba R, Ueno N, et al. 2005. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 23:422-31
25. Potti A, Dressman HK, Bild A, et al. 2006. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12:1294-300
26. Muss HB, Thor AD, Berry DA, et al. 1994. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330:1260-66
27. Paik S, Bryant J, Park C, et al. 1998. erbB-2 and response to doxorubicin in patients with axillary lymph node - positive, hormone receptor - negative breast cancer. J. Natl. Cancer Inst. 90:1361-70
28. Järvinen TA, Tanner M, Barlund M, et al. 1999. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-50
29. Pritchard KI, Messersmith H, Elavathil L, et al. 2008. HER-2 and topoisomerase II as predictors of response to chemotherapy. J. Clin. Oncol. 26:736-44
30. Knoop AS, Knudsen H, Balslev E, et al. 2005. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 23:7483-90
31. Osborne CK. 1998. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339:1609-18
32. Jansen MP, Foekens JA, van Staveren IL, et al. 2005. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 23:732-40
33. Ma XJ, Wang Z, Ryan PD, et al. 2004. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-16
34. Ma XJ, Hilsenbeck SG, Wang W, et al. 2006. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J. Clin. Oncol. 24:4611-19
35. Andre F, Hatzis C, Anderson K, et al. 2007. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin. Cancer Res. 13:2061-67
36. Smith IE, Dowsett M. 2003. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348:2431-42
37. Hennessy BT, Gauthier AM, Michaud LB, et al. 2005. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann. Oncol. 16:1289-96
38. van Kuilenburg AB, Haasjes J, Richel DJ, et al. 2000. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6:4705-12
39. Milano G, Etienne MC, Pierrefite V, et al. 1999. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer 79:627-30
40. Takai S, Fernandez-Salguero P, Kimura S, et al. 1994. Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization. Genomics 24:613-14
41. van Kuilenburg AB. 2004. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40:939-50
42. Hooiveld EA, van Kuilenburg AB, Haanen JB,Westermann AM. 2004. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency]. Ned. Tijdschr. Geneeskd. 148:626-28
43. Stearns V, Johnson MD, Rae JM, et al. 2003. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95:1758-64
44. Jin Y, Desta Z, Stearns V, et al. 2005. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97:30-39
45. Rae JM, Goetz MP, Hayes DF, et al. 2005. CYP2D6 genotype and tamoxifen response. Breast Cancer Res. 7:E6
46. Goetz MP,Rae JM, Suman VJ, et al. 2005. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23:9312-18
47. Colomer R, Monzo M, Tusquets I, et al. 2008. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin. Cancer Res. 14:811-16
48. Macaluso M, Montanari M, Cinti C, Giordano A. 2005. Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 32:452-57
49. Iwase H, Omoto Y, Iwata H, et al. 1999. DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. Br. J. Cancer 80:1982-86
50. Lapidus RG, Nass SJ, Butash KA, et al. 1998. Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res. 58:2515-19
51. Yang X, Phillips DL, Ferguson AT, et al. 2001. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 61:7025-29
52. Jazaeri AA, Yee CJ, Sotiriou C, et al. 2002. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl. Cancer Inst. 94:990-1000
53. Schmidt-Kittler O, Ragg T, Daskalakis A, et al. 2003. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl. Acad. Sci. USA 100:7737-42
54. Braun S, Vogl FD, Naume B, et al. 2005. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 353:793-802
55. Pachmann K, Camara O, Kavallaris A, et al. 2008. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J. Clin. Oncol. 26:1208-15
56. Cristofanilli M, Budd GT, Ellis MJ, et al. 2004. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351:781-91